Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Haemophiliacs and their treatment – danger signals involved in immune response against factor-VIII

28.03.2018

In patients with haemophilia A, the missing blood coagulation factor VIII is administered, and thus replaced, intravenously. A part of the patients, however, develops antibodies (inhibitors) against factor VIII, which, in the worst case scenario, can cause uncontrolled bleeding. Researchers of the Paul-Ehrlich-Institut (PEI) have now established that the adverse immune reactions occur in the presence of so-called danger signals. After antigen processing, mainly memory T cells are activated. The results are published in Thromb. Haemost. in its online edition of 19 March 2018.

Haemophilia A is the most common congenital blood coagulation disorder. It is caused by various mutations in the so-called factor VIII (F8) gene. Depending on the type of mutation, the coagulation factor VIII is not formed in sufficient quantities or is missing entirely.


Photographic image taken under an electron microscope: Red blood cells, leukocytes and platelets

National Cancer Institute

The missing coagulation factor is replaced by intravenous administration of so-called factor-VIII concentrates. However, around a quarter of treated patients who have severe haemophilia develop antibodies against factor VIII – the body treats the coagulations factor like a foreign body and inactivates it using its immune system.

One essential risk factor for the development of these inhibitors is a pronounced F8 mutation. However, not all patients who have such a mutation develop inhibitors, and, vice versa, inhibitors can also be found in a part of the patients with only minor alterations of the F8 gene. What complicates understanding the underlying mechanisms even more is that antibodies against factor VIII can be detected in some healthy individuals, too.

Inhibitors against factor-VIII concentrates partly make treatments of the patients concerned very difficult, and in extreme cases, they can lead to uncontrollable bleedings. For this reason, the team of scientists of Dr Zoe Waibler, head of Section Product Testing of Immunological Biomedicines of the Division Immunology at the Paul-Ehrlich-Institut has performed research on the underlying mechanisms in search of a possibility to prevent the formation of these inhibitors.

In previous research activities, she and her team had shown that certain “danger signals” in the blood such as particular surface molecules of bacteria (LPS, lipopolysaccharides) that warn the body of a pathogenic agent will increase the immunogenicity of factor-VIII products [1]. Immunogenicity describes the ability of molecules to elicit an immune reaction. Another example of this is cell stress resulting from surgical intervention, which transmits danger signals by releasing particular substances.

The increased immunogenicity of factor-VIII products causes so-called dendritic cells (DCs) to be activated to an increasing extent. These immune cells present antigens on their surface, i.e. molecular structures against which an immune response can be mediated. They form part of the innate immune system. In connection with other molecules, this leads to the formation of a subgroup of immune cells of the acquired immune system, the CD4-positive T cells, which are also called T helper cells.

Waibler’s team was now able to show that DCs, which are activated by the factor-VIII concentrate and the danger signal LPS synergistically, mediate a considerably stronger T helper cell activation than DCs, which were pre-treated solely with either factor VIII or LPS alone. In addition, they were able to clarify the dependency of T-cell activation on further immunological processing steps.

“Our results are another step on the road towards clarifying these complex immunological processes. This is a prerequisite for developing new approaches to haemophilia therapies which prevent the formation of these inhibitors against factor-VIII products”, said Waibler when explaining the significance of the results.

1. Miller L et al.: Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost. 2015 Aug;114(2):268-76

Original publication:
(DOI:)

Miller L, Ringler E, Kistner KM, Waibler Z; ABIRISK Consortium (2017): Human dendritic cells synergistically activated by FVIII plus LPS induce activation of autologous CD4+ T cells. Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637734

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute. The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

https://www.ncbi.nlm.nih.gov/pubmed/?term=Human+dendritic+cells+synergistically+... - Abstract
https://www.pei.de/EN/information/journalists-press/press-releases/2018/05-haemo... press release

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht New therapeutic approach to combat African sleeping sickness
20.02.2019 | Johannes Gutenberg-Universität Mainz

nachricht 'Butterfly-shaped' palladium subnano cluster built in 3-D
20.02.2019 | Institute of Industrial Science, The University of Tokyo

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light from a roll – hybrid OLED creates innovative and functional luminous surfaces

Up to now, OLEDs have been used exclusively as a novel lighting technology for use in luminaires and lamps. However, flexible organic technology can offer much more: as an active lighting surface, it can be combined with a wide variety of materials, not just to modify but to revolutionize the functionality and design of countless existing products. To exemplify this, the Fraunhofer FEP together with the company EMDE development of light GmbH will be presenting hybrid flexible OLEDs integrated into textile designs within the EU-funded project PI-SCALE for the first time at LOPEC (March 19-21, 2019 in Munich, Germany) as examples of some of the many possible applications.

The Fraunhofer FEP, a provider of research and development services in the field of organic electronics, has long been involved in the development of...

Im Focus: Regensburg physicists watch electron transfer in a single molecule

For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.

The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...

Im Focus: University of Konstanz gains new insights into the recent development of the human immune system

Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens

Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...

Im Focus: Transformation through Light

Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light

When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...

Im Focus: Famous “sandpile model” shown to move like a traveling sand dune

Researchers at IST Austria find new property of important physical model. Results published in PNAS

The so-called Abelian sandpile model has been studied by scientists for more than 30 years to better understand a physical phenomenon called self-organized...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Global Legal Hackathon at HAW Hamburg

11.02.2019 | Event News

The world of quantum chemistry meets in Heidelberg

30.01.2019 | Event News

Our digital society in 2040

16.01.2019 | Event News

 
Latest News

New therapeutic approach to combat African sleeping sickness

20.02.2019 | Life Sciences

Powering a pacemaker with a patient's heartbeat

20.02.2019 | Medical Engineering

The holy grail of nanowire production

20.02.2019 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>